Welcome to our dedicated page for Century Therapeutics SEC filings (Ticker: IPSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Century Therapeutics鈥� SEC filings rarely read like simple financial statements. Each 10-K weaves stem-cell science, 础濒濒辞-贰惫补蝉颈辞苍鈩� gene edits and cash-burn projections into 200+ pages, leaving investors hunting for clear answers. Stock Titan fixes that problem.
Our AI-powered reader turns every Century Therapeutics SEC filing into plain-English insights. Want the latest 鈥淐entury Therapeutics quarterly earnings report 10-Q filing鈥� summarized before the market opens? We tag key figures鈥擱&D spend, clinical trial milestones, liquidity runway鈥攁nd deliver context in seconds. Need 鈥淐entury Therapeutics insider trading Form 4 transactions鈥� alerts? AG真人官方-time feeds flag executive stock moves, so you can follow 鈥淐entury Therapeutics executive stock transactions Form 4鈥� without refreshing EDGAR.
You鈥檒l find every document, from the 鈥淐entury Therapeutics annual report 10-K simplified鈥� to 鈥淐entury Therapeutics 8-K material events explained,鈥� all indexed the moment they hit the SEC. Our platform connects forms to what matters for this particular biotech:
- 10-K: Pipeline status, manufacturing capacity and 础濒濒辞-贰惫补蝉颈辞苍鈩� IP disclosures
- 10-Q: Quarterly cash burn and trial read-outs
- 8-K: Partnership deals, FDA designations and clinical setbacks
- DEF 14A proxy: 鈥淐entury Therapeutics proxy statement executive compensation鈥� showing R&D incentive structures
- Form 4: 鈥淐entury Therapeutics Form 4 insider transactions real-time鈥� for sentiment signals before data drops
Stop scrolling through dense PDFs. Stock Titan鈥檚 expert analysis, natural-language summaries and adjustable redline comparisons let you understand 鈥淐entury Therapeutics SEC filings explained simply鈥� and act on them faster.
Century Therapeutics (IPSC) reported operational updates reflecting continued development of its iPSC-derived cell therapy pipeline and recent acquisition activity. The company disclosed 86,322,071 shares outstanding at June 30, 2025 versus 85,836,429 at December 31, 2024. Century completed the acquisition of Clade, issuing 3,741,646 common shares at close and recording holdback shares of up to 793,687 subject to indemnification adjustments. Contingent consideration at closing included a fair-value amount of $2,600 plus a potential Clade milestone valued at $8,883, and a possible milestone payment of $10,000 payable in cash, shares, or combination.
The filing outlines program progress and capabilities including lead candidate CNTY-101, preclinical programs from Clade, and additional CAR-iT candidates (CNTY-308, CNTY-341) using the company鈥檚 础濒濒辞-贰惫补蝉颈辞苍鈩� and iPSC platforms. The company reported prior ATM sales of 4,084,502 shares for net proceeds of $17,829 in the six months ended June 30, 2024 and no ATM sales in the six months ended June 30, 2025. Quarter-over-quarter operating expense shifts include G&A of $7.8M versus $8.3M in the prior-year quarter and mixed R&D and facility cost changes driven by staff reductions, consolidation of lab operations, and completion of a manufacturing campaign under the FCDI collaboration.
FAQ
What is the current stock price of Century Therapeutics (IPSC)?
What is the market cap of Century Therapeutics (IPSC)?
